Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Profit After Tax (2016 - 2026)

Niagen Bioscience has reported Profit After Tax over the past 16 years, most recently at $4.1 million for Q4 2025.

  • Quarterly Profit After Tax fell 42.44% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Dec 2025, up 103.3% year-over-year, with the annual reading at $17.4 million for FY2025, 103.3% up from the prior year.
  • Profit After Tax was $4.1 million for Q4 2025 at Niagen Bioscience, down from $4.6 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $7.2 million in Q4 2024 and troughed at -$8.9 million in Q3 2021.
  • The 5-year median for Profit After Tax is -$972000.0 (2022), against an average of -$1.1 million.
  • Year-over-year, Profit After Tax plummeted 110.11% in 2021 and then surged 24160.0% in 2025.
  • A 5-year view of Profit After Tax shows it stood at -$5.3 million in 2021, then soared by 73.37% to -$1.4 million in 2022, then skyrocketed by 108.04% to $114000.0 in 2023, then surged by 6197.37% to $7.2 million in 2024, then tumbled by 42.44% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Profit After Tax are $4.1 million (Q4 2025), $4.6 million (Q3 2025), and $3.6 million (Q2 2025).